The sustainable way to resolve the burden of chronic diseases is prevention. Our blood analysis enables early disease risk prediction of both individuals and populations.
Preventive healthcare for everyone
Actionable personalized medicine
Current risk models are typically based on a limited number of measures yielding “one-size-fits-all” models. Experts widely acknowledge that the key enabler of precision medicine is the ability to stratify patients, taking into account the individual differences in phenotype. Nightingale’s blood analysis is fit for purpose to do exactly that.
With Nightingale’s blood analysis, physicians will be able to identify, follow up, and reclassify patients more accurately according to their individual disease risk. The real-time information on the disease risk is actionable by nature enabling more personalized guidance and treatment.
Chronic diseases typically develop without symptoms and after onset, cause major individual burden. Wouldn't it be great to be able to identify the risk early and to be able to manage the development of the disease?
Nightingale’s blood analysis enables early identification of disease risk and can be used to track the effects of lifestyle and diet interventions on an individual level. Through early identification, we can empower individuals to take control over their own health.
Population-level health screening
The ability to track population-level health state and the impact of care on a molecular level, provides transformative possibilities to build operational, nationwide health policies. With Nightingale’s platform, the effect of a health policy can be evaluated within months to years, rather than decades. Rapid and accurate risk profiling predicts the health outcomes and allows timely feedback on the effect of interventions. This takes us towards reducing the enormous cost burden of chronic diseases.
Realizing preventive healthcare
Nightingale blood analysis panel will be introduced to the clinical market in 2017. The risk prediction power of the panel will continuously improve as we add more biomarkers and build novel risk scores based on population cohorts and a strong evidence base.
Stay in the know!
Subscribe to our newsletter